Download Files:
NYX-2925
$350 – $6,400
Products Details
Product Description
– NYX-2925 is an orally active NMDAR modulator. NYX-2925 restores levels of activated Src and Src phosphorylation sites on GluN2A and GluN2B in the mPFC. NYX-2925 shows no effect on CAMKII, and any addictive or sedative/ataxic side effects. NYX-2925 can be used for research of a variety of NMDA receptor-mediated central nervous system disorders[1][2].
Web ID
– HY-135741
Storage Temperature
– 4°C (Powder, protect from light, stored under nitrogen)
Shipping
– Room Temperature
Applications
– Neuroscience-Neurodegeneration
Molecular Formula
– C14H23N3O4
References
– [1]Morrison G, et al. The NMDAR modulator NYX-2925 alleviates neuropathic pain via a Src-dependent mechanism in the mPFC. Neurobiol Pain. 2019 Dec 4;7:100039. |[2]Khan MA, et al. NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory. Int J Neuropsychopharmacol. 2018 Mar 1;21(3):242-254.
CAS Number
– 2012536-16-0
Molecular Weight
– 297.35
Compound Purity
– 98.77
SMILES
– CC(C)C(N1[C@@]2(CCC1)C(N(C2)[C@H](C(N)=O)[C@H](O)C)=O)=O
Clinical Information
– Phase 2
Research Area
– Neurological Disease
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– iGluR
Isoform
– NMDA Receptor
Pathway
– Membrane Transporter/Ion Channel;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
